SM Number: SM27905
Status: Closed by LRO
Type: In-house
Subject Matter: Economic Development;Grants / Funding;Planning and Development, Planning Policy / Study
Particulars: BlueRock is seeking advice and advocacy as part of an opportunity assessment considering GTA for a future commercial manufacturing facility.
Proposed Start Date: 2019-03-21
Proposed End Date: 2019-12-31
Initial Approval Date: 2019-03-21
Effective Date: 2020-05-29
| Id | Report ID | Type | Name | Trade Name | Description | Business Type | Address |
|---|---|---|---|---|---|---|---|
| 12718 | SM27905 | FirmType.IN_HOUSE | BlueRock Therapeutics Canada ULC | None | BlueRock is a regenerative medicine cell therapy company developing novel treatments for cardiac, neurology and autoimmune diseases. | FirmBusinessType.CORPORATION | 101 College St, BlueRock Therapeutics, PMCRT 14-301, Toronto, Ontario, Canada, M5G 1L7 |
| 12719 | SM27905 | FirmType.PARENT | BlueRock Therapeutics | None | None | None | 1 Broadway, 15th Floor, Cambridge, MA, None, 02142 |